James Noble

Chief Executive Officer

James Noble

James Noble has been involved with Adaptimmune’s adoptive T cell therapy technology since 1999, when Avidex Limited (the predecessor company to Adaptimmune) was founded. He has over two decades of experience in biotechnology and has served on public and private boards of companies in the UK, the USA and Germany. He is currently Deputy Chairman at GW Pharmaceuticals plc, an AIM-listed biotech company, and is also CEO of Immunocore, Adaptimmune’s sister company focused on T cell therapy.

Company Spotlight

ImmunoGen

ImmunoGen

Back to top